Which has preferable valuation & earnings, DBVT or MANE?

Veradermics has lower revenue, but higher earnings than DBV Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DBV Technologies $5.64M 169.13 -$146.95M -$4.46 N/A Veradermics N/A N/A N/A N/A N/A

Does the media favor DBVT or MANE?

In the previous week, Veradermics had 2 more articles in the media than DBV Technologies. MarketBeat recorded 3 mentions for Veradermics and 1 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.00 beat Veradermics' score of 0.94 indicating that DBV Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DBVT or CRNX?

In the previous week, Crinetics Pharmaceuticals had 5 more articles in the media than DBV Technologies. MarketBeat recorded 6 mentions for Crinetics Pharmaceuticals and 1 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.00 beat Crinetics Pharmaceuticals' score of 0.57 indicating that DBV Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DBVT or ACAD?

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than DBV Technologies. MarketBeat recorded 4 mentions for ACADIA Pharmaceuticals and 1 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.00 beat ACADIA Pharmaceuticals' score of 0.56 indicating that DBV Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DBV Technologies (DBVT) Competitors

$16.11 +0.41 (+2.61%)

As of 04:00 PM Eastern

Compare

DBVT vs. KNSA, MANE, CPRX, CRNX, and ACAD

Should you buy DBV Technologies stock or one of its competitors? MarketBeat compares DBV Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DBV Technologies include Kiniksa Pharmaceuticals International (KNSA), Veradermics (MANE), Catalyst Pharmaceuticals (CPRX), Crinetics Pharmaceuticals (CRNX), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry.

How does DBV Technologies compare to Kiniksa Pharmaceuticals International?

DBV Technologies (NASDAQ:DBVT) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to DBV Technologies' net margin of -2,895.37%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

Kiniksa Pharmaceuticals International has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	169.13	-$146.95M	-$4.46	N/A
Kiniksa Pharmaceuticals International	$754.05M	6.07	$59.01M	$0.90	66.10

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

DBV Technologies has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

DBV Technologies currently has a consensus price target of $48.50, indicating a potential upside of 201.06%. Kiniksa Pharmaceuticals International has a consensus price target of $60.86, indicating a potential upside of 2.30%. Given DBV Technologies' higher probable upside, equities research analysts plainly believe DBV Technologies is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Kiniksa Pharmaceuticals International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.11

In the previous week, Kiniksa Pharmaceuticals International had 5 more articles in the media than DBV Technologies. MarketBeat recorded 6 mentions for Kiniksa Pharmaceuticals International and 1 mentions for DBV Technologies. Kiniksa Pharmaceuticals International's average media sentiment score of 1.14 beat DBV Technologies' score of 1.00 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiniksa Pharmaceuticals International	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kiniksa Pharmaceuticals International beats DBV Technologies on 13 of the 17 factors compared between the two stocks.

How does DBV Technologies compare to Veradermics?

DBV Technologies (NASDAQ:DBVT) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Veradermics has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. Veradermics' return on equity of 0.00% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
Veradermics	N/A	N/A	N/A

71.7% of DBV Technologies shares are held by institutional investors. 1.1% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

DBV Technologies currently has a consensus target price of $48.50, indicating a potential upside of 201.06%. Veradermics has a consensus target price of $114.20, indicating a potential upside of 9.93%. Given DBV Technologies' stronger consensus rating and higher possible upside, equities research analysts plainly believe DBV Technologies is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Veradermics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Veradermics has lower revenue, but higher earnings than DBV Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	169.13	-$146.95M	-$4.46	N/A
Veradermics	N/A	N/A	N/A	N/A	N/A

In the previous week, Veradermics had 2 more articles in the media than DBV Technologies. MarketBeat recorded 3 mentions for Veradermics and 1 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.00 beat Veradermics' score of 0.94 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DBV Technologies beats Veradermics on 7 of the 12 factors compared between the two stocks.

How does DBV Technologies compare to Catalyst Pharmaceuticals?

DBV Technologies (NASDAQ:DBVT) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Catalyst Pharmaceuticals has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	169.13	-$146.95M	-$4.46	N/A
Catalyst Pharmaceuticals	$588.99M	6.53	$214.33M	$1.74	18.05

DBV Technologies has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

In the previous week, DBV Technologies had 1 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 1 mentions for DBV Technologies and 0 mentions for Catalyst Pharmaceuticals. DBV Technologies' average media sentiment score of 1.00 beat Catalyst Pharmaceuticals' score of 0.00 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
DBV Technologies	Positive
Catalyst Pharmaceuticals	Neutral

DBV Technologies presently has a consensus price target of $48.50, indicating a potential upside of 201.06%. Catalyst Pharmaceuticals has a consensus price target of $32.00, indicating a potential upside of 1.91%. Given DBV Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe DBV Technologies is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Catalyst Pharmaceuticals has a net margin of 37.08% compared to DBV Technologies' net margin of -2,895.37%. Catalyst Pharmaceuticals' return on equity of 35.76% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 1.1% of DBV Technologies shares are held by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Catalyst Pharmaceuticals beats DBV Technologies on 10 of the 16 factors compared between the two stocks.

How does DBV Technologies compare to Crinetics Pharmaceuticals?

DBV Technologies (NASDAQ:DBVT) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

DBV Technologies has a beta of -0.99, suggesting that its share price is 199% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Crinetics Pharmaceuticals has a net margin of -2,747.18% compared to DBV Technologies' net margin of -2,895.37%. Crinetics Pharmaceuticals' return on equity of -43.96% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%

DBV Technologies has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	169.13	-$146.95M	-$4.46	N/A
Crinetics Pharmaceuticals	$7.70M	491.73	-$465.32M	-$5.13	N/A

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 1.1% of DBV Technologies shares are held by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

DBV Technologies currently has a consensus target price of $48.50, indicating a potential upside of 201.06%. Crinetics Pharmaceuticals has a consensus target price of $76.13, indicating a potential upside of 111.99%. Given DBV Technologies' higher probable upside, equities research analysts clearly believe DBV Technologies is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Crinetics Pharmaceuticals had 5 more articles in the media than DBV Technologies. MarketBeat recorded 6 mentions for Crinetics Pharmaceuticals and 1 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.00 beat Crinetics Pharmaceuticals' score of 0.57 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Crinetics Pharmaceuticals beats DBV Technologies on 11 of the 17 factors compared between the two stocks.

How does DBV Technologies compare to ACADIA Pharmaceuticals?

DBV Technologies (NASDAQ:DBVT) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than DBV Technologies. MarketBeat recorded 4 mentions for ACADIA Pharmaceuticals and 1 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.00 beat ACADIA Pharmaceuticals' score of 0.56 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DBV Technologies has a beta of -0.99, suggesting that its share price is 199% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to DBV Technologies' net margin of -2,895.37%. ACADIA Pharmaceuticals' return on equity of 9.61% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

DBV Technologies currently has a consensus price target of $48.50, indicating a potential upside of 201.06%. ACADIA Pharmaceuticals has a consensus price target of $31.63, indicating a potential upside of 39.93%. Given DBV Technologies' stronger consensus rating and higher possible upside, analysts plainly believe DBV Technologies is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
ACADIA Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 1.1% of DBV Technologies shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ACADIA Pharmaceuticals has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	169.13	-$146.95M	-$4.46	N/A
ACADIA Pharmaceuticals	$1.07B	3.61	$391M	$2.20	10.27

Summary

ACADIA Pharmaceuticals beats DBV Technologies on 12 of the 17 factors compared between the two stocks.

Get DBV Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DBVT vs. The Competition

Export

Metric	DBV Technologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$929.63M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-3.61	19.75	24.92	23.98
Price / Sales	169.13	330.11	529.01	109.54
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	3.84	8.29	10.79	6.50
Net Income	-$146.95M	$23.85M	$3.56B	$336.88M
7 Day Performance	-3.82%	5.21%	1.67%	-0.22%
1 Month Performance	-11.39%	2.19%	0.43%	0.77%
1 Year Performance	88.20%	60.99%	32.84%	31.57%

DBV Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DBVT DBV Technologies	3.5361 of 5 stars	$16.11 +2.6%	$48.50 +201.1%	+67.0%	$929.63M	$5.64M	N/A	80	Positive News
KNSA Kiniksa Pharmaceuticals International	3.4985 of 5 stars	$52.10 -0.5%	$60.86 +16.8%	+100.9%	$4.02B	$677.56M	58.07	220	Positive News
MANE Veradermics	N/A	$94.93 -1.4%	$114.20 +20.3%	N/A	$3.97B	N/A	N/A	19
CPRX Catalyst Pharmaceuticals	2.8876 of 5 stars	$31.38 +0.0%	$32.00 +2.0%	+39.6%	$3.84B	$596.96M	18.03	80	Positive News
CRNX Crinetics Pharmaceuticals	3.3714 of 5 stars	$34.81 -0.9%	$76.13 +118.7%	+17.3%	$3.67B	$7.70M	N/A	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DBVT) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DBV Technologies (DBVT) Competitors

DBVT vs. KNSA, MANE, CPRX, CRNX, and ACAD

How does DBV Technologies compare to Kiniksa Pharmaceuticals International?

Summary

How does DBV Technologies compare to Veradermics?

Summary

How does DBV Technologies compare to Catalyst Pharmaceuticals?

Summary

How does DBV Technologies compare to Crinetics Pharmaceuticals?

Summary

How does DBV Technologies compare to ACADIA Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT vs. The Competition

DBV Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DBV Technologies (DBVT) Competitors

DBVT vs. KNSA, MANE, CPRX, CRNX, and ACAD

How does DBV Technologies compare to Kiniksa Pharmaceuticals International?

Is DBVT or KNSA more profitable?

Which has higher earnings and valuation, DBVT or KNSA?

Do insiders & institutionals have more ownership in DBVT or KNSA?

Which has more risk & volatility, DBVT or KNSA?

Do analysts rate DBVT or KNSA?

Does the media prefer DBVT or KNSA?

Summary

How does DBV Technologies compare to Veradermics?

Is DBVT or MANE more profitable?

Do institutionals and insiders believe in DBVT or MANE?

Do analysts recommend DBVT or MANE?

Which has preferable valuation & earnings, DBVT or MANE?

Does the media favor DBVT or MANE?

Summary

How does DBV Technologies compare to Catalyst Pharmaceuticals?

Which has stronger earnings and valuation, DBVT or CPRX?

Which has more volatility & risk, DBVT or CPRX?

Does the media prefer DBVT or CPRX?

Do analysts recommend DBVT or CPRX?

Is DBVT or CPRX more profitable?

Do institutionals & insiders believe in DBVT or CPRX?

Summary

How does DBV Technologies compare to Crinetics Pharmaceuticals?

Which has more volatility & risk, DBVT or CRNX?

Is DBVT or CRNX more profitable?

Which has stronger valuation & earnings, DBVT or CRNX?

Do institutionals and insiders believe in DBVT or CRNX?

Do analysts rate DBVT or CRNX?

Does the media refer more to DBVT or CRNX?

Summary

How does DBV Technologies compare to ACADIA Pharmaceuticals?

Does the media prefer DBVT or ACAD?

Which has more risk & volatility, DBVT or ACAD?

Is DBVT or ACAD more profitable?

Do analysts prefer DBVT or ACAD?

Do insiders and institutionals believe in DBVT or ACAD?

Which has higher valuation & earnings, DBVT or ACAD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT vs. The Competition

DBV Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools